Finally, it should be mentioned that TAI‐95, a NDC80 inhibitor, has been proved to be superior in inhibiting the in vitro growth of primary liver cancer cells as compared with some current targeted agents such as sorafenib 20. The gene discussed is NDC80; the disease is liver cancer.